In this scenario, it could be hypothesized the evaluation of novel combination therapies (i.e. DNA damaging agents plus anti-angiogenic drugs) in subgroup of breast cancer patients carrying BRCA1-2 mutations. Here, BRCA1 is linked to breast cancer.